Evidence map›Paper›PMID 26539160›Full record

ReviewFrontiers in endocrinology2015

New Frontier in Glycoprotein Hormones and Their Receptors Structure-Function.

Mariusz W Szkudlinski

Abstract readReview
In one paragraph

Review in Frontiers in endocrinology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Mariusz W SzkudlinskiTrophogen Inc. , Rockville, MD , USA.

Funding

Novel Long Acting rhTSH Superagonist Analogs for Improved Diagnostic Imaging, Thyroglobulin Stimulation and Therapy of Thyroid Cancer.R44CA224376 · NCI · TROPHOGEN, INC. · PI SZKUDLINSKI, MARIUSZ WALDEMAR, WEINTRAUB, BRUCE DALE · 2018 to 2021
$1.8M
Novel Recombinant High-Affinity, Long- and Dual-Acting Equine CG Analogs for Improved and More Ethical Reproduction in Pigs and CattleR44HD094408 · NICHD · TROPHOGEN, INC. · PI SZKUDLINSKI, MARIUSZ WALDEMAR, WEINTRAUB, BRUCE DALE · 2019 to 2020
$1.5M
Novel Recombinant High-Affinity, Long- and Dual-Acting Equine CG Analogs for Improved and More Ethical Reproduction in Pigs and CattleR43HD094408 · NICHD · TROPHOGEN, INC. · PI SZKUDLINSKI, MARIUSZ WALDEMAR, WEINTRAUB, BRUCE DALE · 2017 to 2017
$139k
FDA HHS R43 FD004417NCI NIH HHS R44 CA224376NICHD NIH HHS R43 HD094408NICHD NIH HHS R44 HD094408
6 · The paper itself

Abstract

Last two decades of structure-function studies performed in numerous laboratories provided substantial progress in understanding basic science, physiological, pathophysiological, pharmacological, and comparative aspects of glycoprotein hormones (GPHs) and their cognate receptors. Multiple concepts and models developed based on experimental data in the past stood the test of time and have been, at least in part, confirmed and/or remained compatible with the new structures resolved at the atomic level. Major advances in understanding of the ligand-receptor relationships are heralding the dawn of a new era for GPHs and their receptors, although many basic questions still remain unanswered. This article examines retrospectively several basic science aspects of GPH super-agonists and related "biosuperiors" in a broader context of the advances in the ligand-receptor structure-function relationships and new mechanistic models generated based on the structure elucidation. Due to selective focus of my comments and perspectives in certain parts, the reader is directed to the most relevant publications and reviews in the field for more comprehensive analyses.

Indexed as

biobetterbiosuperiorcharge clusterglycoprotein hormoneglycoprotein hormone receptorprotein engineeringstructure–functionsuper–agonist

Identifiers

PMID26539160
PMCPMC4609891

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.